NEW YORK, March 7, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Theravance Inc (NASDAQ: THRX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Infinity Pharmaceuticals Inc. (NASDAQ: INFI) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
Pfizer recently presented the results from the Phase 3 study of Prevnar 13 in adults infected with HIV at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). The study demonstrated the drug's immunogenicity, tolerability and safety. The research was made to minimize the threat of infectious diseases to adults with weakened immune systems. Two weeks ago, Pfizer also presented results for a Phase 3 study showing Lyrica's efficacy as an adjunctive therapy in adult epilepsy patients experiencing partial seizures. With a highly active R&D department presenting positive results, Pfizer is continuing to strengthen its pipeline and improve its prospects. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/e0bd_PFE]
--
Theravance Inc Research Report
Theravance shares rallied by as much as 18 percent after a Piper Jaffray analyst said that the approval Therevance's respiratory drugs could lead to a takeover by GlaxoSmithKline. Theravance is co-developing Breo and Anoro with GlaxoSmithKline, drugs that treat chronic respiratory diseases. The FDA is scheduled to review Breo on Thursday and is expected to give their final decision on May 12. The final decision for Anoro is due on December 12. Whether or not GlaxoSmithKline decides to buy Theravance, Breo sales are still expected total around $314 million in 2014 and grow to about $1.25 billion by 2017 if the drug is approved this year, according to Thomson Pharma. With two pending drug approvals and a potential buyout from Britain's biggest drug maker, the outlook for Theravance looks bright. The Full Research Report on Theravance Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b77f_THRX]
--
ISIS Pharmaceuticals, Inc. Research Report
ISIS Pharmaceuticals recently reported its 2012 financial results. The company highlighted NOL of $60.4 million compared to $61.3 million in 2011.The FDA approval of KYNAMRO, the first systemic antisense drug, was one of the highlights. In addition, ISIS Pharmaceuticals expects to report late-stage clinical data on promising new drugs within the year. Moving forward, ISIS expects to further advance its pipeline and also expects Genzyme to help push KYNAMRO's commercial success. ISIS Pharmaceuticals' ongoing partnerships with leading drug makers remain encouraging. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/bf5f_ISIS]
--
Infinity Pharmaceuticals Inc. Research Report
Shares of Infinity Pharmaceuticals jumped after a Piper Jaffray analyst claimed that the company's experimental drug will be approved to treat several types of cancer, with annual sales of $3 billion. Analyst Ian Somaiya initiated coverage on Infinity Pharmaceuticals shares with an "Overweight" rating and expects the shares to rise higher after the company reports results from early clinical trials of the drug IPI-145. Another drug that Infinity is developing is IPI-504. Many are already expecting massive long-term growth for Infinity after its drugs finish trials around 2019, driven by a promising pipeline. The Full Research Report on Infinity Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d603_INFI]
--
Ironwood Pharmaceuticals, Inc. Research Report
Ironwood recently appointed Edward Owens, a recently retired partner, portfolio manager and global industry analyst with Wellington Management Company to its Board of Directors. Mr. Owens comments that Ironwood will be one of the next growth companies in biotech. Furthermore, he asserts that Ironwood's successful launch of LINZESS should provide Ironwood what it needs to build an exceptional business. Moving forward, Ironwood will focus on further increasing the sales of LINZESS and strengthening the clinical profile of Constella, the treatment of moderate to severe irritable bowel syndrome. Its pipeline includes IW-9179 for functional dyspepsia and IW-2143 for anxiety. By advancing its pipeline, Ironwood is set to reach its goal of providing differentiated medicines and deliver for investors. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/ec5d_IRWD]
--
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826
SOURCE Investors-Alliance